Feb 18 (Reuters) - Opioid addiction treatment maker Indivior said on Thursday annual revenue fell 18%, hit by a decline in demand for its best-selling drug due to cheaper rivals and as patients stayed away from hospitals during the COVID-19 pandemic.
The company said revenue fell to $647 million in the 12 months ended Dec. 31, from $785 million a year ago. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Sriraj Kalluvila)
我们的标准: 汤森路透“信任原则”